Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing-Remitting Multiple Sclerosis (RRMS)”

Showing 20 of 0 results

Post-approval studies (Phase 4)Active Not RecruitingNCT03535298
What this trial is testing

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
The Cleveland Clinic 800
Not applicableStudy completedNCT03134573
What this trial is testing

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Who this might be right for
Multiple Sclerosis
Bayer 96
Not applicableStudy completedNCT05304520
What this trial is testing

Tysabri Participant Preference

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen 318
Early research (Phase 1)Ended earlyNCT01318421
What this trial is testing

ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 12
Post-approval studies (Phase 4)WithdrawnNCT01709812
What this trial is testing

Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals
Not applicableEnded earlyNCT01905527
What this trial is testing

Adherence Trial With MS LifeLines ® Services

Who this might be right for
Multiple SclerosisRelapsing-Remitting
EMD Serono 306
Not applicableLooking for participantsNCT06267781
What this trial is testing

RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies

Who this might be right for
Multiple Sclerosis
IRCCS San Raffaele 30
Not applicableStudy completedNCT02677077
What this trial is testing

Clinical Disease Activity With Long Term Natalizumab Treatment

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 277
Not applicableStudy completedNCT06127095
What this trial is testing

Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 474
Not applicableStudy completedNCT02277964
What this trial is testing

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University Hospital, Basel, Switzerland 25
Not applicableStudy completedNCT01125475
What this trial is testing

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Merck KGaA, Darmstadt, Germany 61
Testing effectiveness (Phase 2)Study completedNCT06812585
What this trial is testing

The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
German University in Cairo 30
Large-scale testing (Phase 3)Study completedNCT00668343
What this trial is testing

Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Tehran University of Medical Sciences 80
Large-scale testing (Phase 3)Study completedNCT02283853
What this trial is testing

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 156
Post-approval studies (Phase 4)Study completedNCT01085318
What this trial is testing

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Who this might be right for
Multiple Sclerosis
EMD Serono 38
Large-scale testing (Phase 3)Study completedNCT02637856
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 608
Not applicableStudy completedNCT01592097
What this trial is testing

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

Who this might be right for
Multiple Sclerosis
University of Southern California 51
Not applicableActive Not RecruitingNCT06345157
What this trial is testing

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals 379
Large-scale testing (Phase 3)Study completedNCT02555215
What this trial is testing

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 20
Large-scale testing (Phase 3)Study completedNCT02579681
What this trial is testing

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 221
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation